Last reviewed · How we verify
NCT01172314
Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients
NA trial testing EAA+LEU vs total AA in Non-small Cell Lung Cancer in 41 participants. Completed in 22 February 2012.
22 February 2012
Quick facts
| Lead sponsor | Texas A&M University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | other |
| Enrollment | 41 |
| Start date | 13 July 2010 |
| Primary completion | 22 February 2012 |
| Estimated completion | 22 February 2012 |
| Sites | 1 location across United States |
Drugs / interventions tested
- EAA+LEU vs total AA
- Total AA vs EAA+LEU
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
Texas A&M University
Who can join
40 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Weight loss commonly occurs in lung cancer patients, negatively influencing their quality of life, treatment response and survival. Gains in lean body mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. It is our hypothesis that a nutritional supplement containing a high amount of essential amino acids will target the metabolic alterations of cancer patients. Preliminary research performed in our laboratory in elderly supports this hypothesis. We hypothesize that intake of an essential amino acid nutritional supplement will positively influence protein synthesis rate in advanced non-small cell lung cancer (NSCLC) patients. Furthermore, insight in the underlying mechanism of the higher anabolic response of the essential amino acid supplement will be examined. This information will potentially enable us to formulate a supplement that is more effective than normal food intake, and that will reduce the need for muscle protein breakdown.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer.
Engelen MPKJ, Safar AM, Bartter T, Koeman F, et al · · 2015 · cited 65× · PMID 26113648 · DOI 10.1093/annonc/mdv271 -
Effectiveness of essential amino acid supplementation in stimulating whole body net protein anabolism is comparable between COPD patients and healthy older adults.
Jonker R, Deutz NE, Erbland ML, Anderson PJ, et al · · 2017 · cited 43× · PMID 28285641 · DOI 10.1016/j.metabol.2016.12.010 -
Alterations in whole-body arginine metabolism in chronic obstructive pulmonary disease.
Jonker R, Deutz NE, Erbland ML, Anderson PJ, et al · · 2016 · cited 30× · PMID 27146652 · DOI 10.3945/ajcn.115.125187 -
Cardiac Cachexia: Unaddressed Aspect in Cancer Patients.
Saha S, Singh PK, Roy P, Kakar SS. · · 2022 · cited 20× · PMID 35326441 · DOI 10.3390/cells11060990
Verify or expand the search:
- PubMed search for NCT01172314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Texas A&M University trials
Trials by the same sponsor.
- NCT07079995 — Healthy School Recognized Campus: A Hybrid Type 2 Implementation-Effectiveness Trial · NA · recruiting
- NCT06950775 — The Neighborhood & Health Study · recruiting
- NCT06890689 — Effectiveness of Scaling and Root Planing in Deeper Pockets · active not recruiting
- NCT06797089 — Does myTAP Oral Appliance Therapy Including a Mouth Shield Lessen Periodontitis in Mouth-Breathers Who Snore? · NA · completed
- NCT05959434 — Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01172314 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas A&M University
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01172314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing